Terms: = Prostate cancer AND RUNX1T1, ENSG00000079102, 862
111 results:
1. One-year clinical outcomes of MR-guided stereotactic body radiation therapy with rectal spacer for patients with localized prostate cancer.
Poon DMC; Yuan J; Wong OL; Yang B; Tse MY; Lau KK; Chiu ST; Chiu PK; Ng CF; Chui KL; Kwong YM; Ma WK; Cheung KY; Chiu G; Yu SK
World J Urol; 2024 Feb; 42(1):97. PubMed ID: 38393414
[TBL] [Abstract] [Full Text] [Related]
2. Rational use of Ga-68 PSMA PET-CT according to nomograms and risk groups for the detection of lymph node metastasis in prostate cancer.
Madendere S; Kılıç M; Köseoğlu E; Aykanat İC; Eden AB; Coşkun B; Tekkalan FB; Balbay MD
Urol Oncol; 2024 Feb; 42(2):29.e9-29.e15. PubMed ID: 38114351
[TBL] [Abstract] [Full Text] [Related]
3. [Accuracy of prostatic ultrasonography versus MRI in measuring prostate volume].
Hou JL; Ma WL; Dong X; Zhu XY; Zhang Q; Qiu XF; Zhuang JL; Huang HF; Guo HQ; Gan WD
Zhonghua Nan Ke Xue; 2022 Oct; 28(10):896-900. PubMed ID: 37838956
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive analysis of predictive factors for upstaging in intraprostatic cancer after radical prostatectomy: Different patterns of spread exist in lesions at different locations.
Wu S; Jiang Y; Liang Z; Chen S; Sun G; Ma S; Chen K; Liu R
Cancer Med; 2023 Sep; 12(17):17776-17787. PubMed ID: 37537798
[TBL] [Abstract] [Full Text] [Related]
5. The predictive value of machine learning and nomograms for lymph node metastasis of prostate cancer: a systematic review and meta-analysis.
Wang H; Xia Z; Xu Y; Sun J; Wu J
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):602-613. PubMed ID: 37488275
[TBL] [Abstract] [Full Text] [Related]
6. The impact of previous inguinal mesh hernioplasty on oncological and patient-reported outcomes following radical prostatectomy.
Westhofen T; Bensel M; Schlenker B; Becker A; Stief CG; Kretschmer A; Buchner A
Prostate; 2023 Oct; 83(14):1313-1322. PubMed ID: 37394751
[TBL] [Abstract] [Full Text] [Related]
7. Regional disparities in cancer survival in Iran: Insight from a National Surveillance of cancer Survival in Iran (IRANCANSURV).
Nemati S; Saeedi E; Lotfi F; Nahvijou A; Pirnejad H; Cheraghi M; Rezaeianzadeh A; Dolatkhah R; Bazarafshan A; Golpazir A; Yaghoobi-Ashrafi M; Abdi S; Alvand S; Ravankhah Z; Mohebbi E; Khosravi A; Etemadi A; Sheikh M; Roshandel G; Ghanbari-Motlagh A; Partovipour E; Najafi F; Malekzadeh R; Mohagheghi MA; Zendehdel K
Cancer Epidemiol; 2023 Aug; 85():102378. PubMed ID: 37229955
[TBL] [Abstract] [Full Text] [Related]
8. European cancer mortality predictions for the year 2023 with focus on lung cancer.
Malvezzi M; Santucci C; Boffetta P; Collatuzzo G; Levi F; La Vecchia C; Negri E
Ann Oncol; 2023 Apr; 34(4):410-419. PubMed ID: 36882139
[TBL] [Abstract] [Full Text] [Related]
9. A Novel Nomogram Combined the Aggregate Index of Systemic Inflammation and PIRADS Score to Predict the Risk of Clinically Significant prostate cancer.
Xie W; Xu Z; Qiu Y; Ye W; Zhang Z; Wang C; Zang J
Biomed Res Int; 2023; 2023():9936087. PubMed ID: 36685670
[TBL] [Abstract] [Full Text] [Related]
10. Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer.
He J; Han Z; Luo W; Shen J; Xie F; Liao L; Zou G; Luo X; Guo Z; Li Y; Li J; Chen H
Front Immunol; 2022; 13():998447. PubMed ID: 36685547
[TBL] [Abstract] [Full Text] [Related]
11. Holmium Laser Enucleation of prostate in Patients with Pre-Existing Localized prostate cancer, Dual Center Study.
Elsaqa M; Slade A; Lingeman J; Piroozi A; Wagner K; Jhavar S; El Tayeb MM
J Endourol; 2023 Mar; 37(3):330-334. PubMed ID: 36463424
[No Abstract] [Full Text] [Related]
12. Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK Biobank.
Green HD; Merriel SWD; Oram RA; Ruth KS; Tyrrell J; Jones SE; Thirlwell C; Weedon MN; Bailey SER
Br J Cancer; 2022 Nov; 127(8):1534-1539. PubMed ID: 35978138
[TBL] [Abstract] [Full Text] [Related]
13. Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study.
Jonušas J; Drevinskaitė M; Patašius A; Kinčius M; Janulionis E; Smailytė G
Aging Male; 2022 Dec; 25(1):173-179. PubMed ID: 35882633
[No Abstract] [Full Text] [Related]
14. [Clinical Statistics From 2017 to 2019 in the Department of Urology, Hospital of the University of the Occupational and Environmental Health, Japan].
Murooka K; Moriya R; Yamasaki G; Iwakuma K; Higashijima K; Onishi R; Minato A; Matsumoto M; Tomisaki I; Fujimoto N
J UOEH; 2022; 44(2):191-196. PubMed ID: 35660685
[TBL] [Abstract] [Full Text] [Related]
15. Causes of Death after prostate cancer Diagnosis: A Population-Based Study.
Guo Y; Dong X; Mao S; Yang F; Wang R; Ma W; Liu J; Li C; Zheng Z; Zhang W; Zhang A; Yao X
Oxid Med Cell Longev; 2022; 2022():8145173. PubMed ID: 35502209
[TBL] [Abstract] [Full Text] [Related]
16. Comparing Iridium-192 with Cobalt-60 sources in high-dose-rate brachytherapy boost for localized prostate cancer.
Tamihardja J; Weick S; Lutyj P; Zimmermann M; Bratengeier K; Flentje M; Polat B
Acta Oncol; 2022 Jun; 61(6):714-719. PubMed ID: 35485446
[TBL] [Abstract] [Full Text] [Related]
17. Comparison of Multiparametric and Fast MRI Protocols in Detecting Clinically Significant prostate cancer and a Detailed Cost Analysis.
Alver KH; Yagci AB; Utebey AR; Turk NS; Ufuk F
J Magn Reson Imaging; 2022 Nov; 56(5):1437-1447. PubMed ID: 35274792
[TBL] [Abstract] [Full Text] [Related]
18. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.
Kang HW; Byun YJ; Moon SM; Kim K; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2022 Mar; 63(2):238-244. PubMed ID: 35244999
[TBL] [Abstract] [Full Text] [Related]
19. Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study.
Hata H; Imamachi K; Ueda M; Matsuzaka M; Hiraga H; Osanai T; Harabayashi T; Fujimoto K; Oizumi S; Takahashi M; Yoshikawa K; Sato J; Yamazaki Y; Kitagawa Y
Support Care Cancer; 2022 May; 30(5):4505-4514. PubMed ID: 35113225
[TBL] [Abstract] [Full Text] [Related]
20. Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.
Bulten W; Kartasalo K; Chen PC; Ström P; Pinckaers H; Nagpal K; Cai Y; Steiner DF; van Boven H; Vink R; Hulsbergen-van de Kaa C; van der Laak J; Amin MB; Evans AJ; van der Kwast T; Allan R; Humphrey PA; Grönberg H; Samaratunga H; Delahunt B; Tsuzuki T; Häkkinen T; Egevad L; Demkin M; Dane S; Tan F; Valkonen M; Corrado GS; Peng L; Mermel CH; Ruusuvuori P; Litjens G; Eklund M;
Nat Med; 2022 Jan; 28(1):154-163. PubMed ID: 35027755
[TBL] [Abstract] [Full Text] [Related]
[Next]
